Table 2.
SIR, RR and AER for any subsequent primary oral cancer by different factors among all cancer survivors in the PanCareSurFup cohort.
| Factor | Level | N (%) | Pyrs | Obs (%) | Exp | SIR (95% CI) | RR (95% CI) | AER (95% CI) |
|---|---|---|---|---|---|---|---|---|
| Overall | 69,460 (100%) | 1,264,634 | 145 (100%) | 29.2 | 5.0 (4.4–5.6) | 9.2 (7.9–10.6) | ||
| Sexa | Males | 37,738 (54.3%) | 676,132 | 89 (61.4%) | 20.3 | 4.4 (3.6–5.4) | 1.0 (ref) | 10.2 (7.8–13.3) |
| Females | 31,722 (45.7%) | 588,502 | 56 (38.6%) | 8.9 | 6.3 (4.8–8.2) | 1.1 (0.8–1.5) | 8.0 (5.9–10.9) | |
| pheterogeneity | 0.04 | 0.61 | 0.25 | |||||
| Type of childhood cancera | Leukaemia | 16,595 (23.9%) | 257,776 | 52 (35.9%) | 2.7 | 19.2 (14.6–25.2) | 6.9 (3.4–13.8) | 19.1 (14.4–25.5) |
| Hodgkin lymphoma | 6000 (8.6%) | 97,380 | 18 (12.4%) | 2.7 | 6.2 (3.9–9.9) | 3.6 (1.7–7.9) | 15.5 (9.0–26.9) | |
| Non-HL | 3350 (4.8%) | 61,167 | 5 (3.4%) | 2.9 | 2.9 (1.2–6.9) | 1.8 (0.6–5.2) | 5.3 (1.4–20.5) | |
| CNS tumour | 14,529 (20.9%) | 261,527 | 10 (6.9%) | 1.8 | 1.5 (0.8–2.7) | 1.0 (ref) | 1.2 (0.2–8.4) | |
| Neuroblastoma | 3169 (4.6%) | 61,639 | 3 (2.1%) | 6.8 | 3.4 (1.1–10.4) | 2.1 (0.6–8.1) | 3.4 (0.7–17.1) | |
| Retinoblastoma | 2578 (3.7%) | 70,267 | 5 (3.4%) | 0.9 | 3.0 (1.3–7.2) | 2.9 (0.9–9.1) | 4.8 (1.3–17.7) | |
| Wilms tumour | 4756 (6.8%) | 108,429 | 4 (2.8%) | 1.7 | 2.0 (0.8–5.5) | 1.3 (0.4–4.4) | 1.9 (0.3–12.8) | |
| Bone Sarcoma | 3147 (4.5%) | 56,775 | 13 (9.0%) | 2.0 | 6.4 (3.7–11.0) | 4.5 (1.9–10.3) | 19.3 (10.1–36.8) | |
| Soft tissue sarcoma | 4501 (6.5%) | 92,019 | 14 (9.7%) | 2.0 | 5.0 (3.0–8.5) | 3.8 (1.7–8.6) | 12.2 (6.3–23.4) | |
| Other | 10,472 (15.1%) | 185,835 | 21 (14.5%) | 2.8 | 4.1 (2.7–6.3) | 3.2 (1.5–6.9) | 8.5 (4.9–15.0) | |
| Unclassified | 363 (0.5%) | – | – | – | – | – | – | |
| pheterogeneity | <0.001 | <0.001 | <0.001 | |||||
| Decade of childhood cancer diagnosisa | <1970 | 8993 (12.9%) | 310,237 | 31 (21.4%) | 16.7 | 1.9 (1.3–2.6) | 1.0 (ref) | 4.6 (2.2–9.9) |
| 1970–1979 | 13,479 (19.4%) | 353,288 | 46 (31.7%) | 7.6 | 6.0 (4.5–8.1) | 1.8 (1.1–3.0) | 10.9 (7.7–15.4) | |
| 1980–1989 | 20,900 (30.1%) | 399,362 | 47 (32.4%) | 3.9 | 12.1 (9.1–16.1) | 2.2 (1.2–3.9) | 10.8 (7.9–14.7) | |
| 1990–2008 | 26,088 (37.6%) | 201,748 | 21 (14.5%) | 1.1 | 19.3 (12.6–29.5) | 2.4 (1.2–5.1) | 9.9 (6.3–15.5) | |
| ptrend | <0.001 | 0.02 | 0.12 | |||||
| Age at childhood cancer (years)a | 0–3 | 22,013 (31.7%) | 438,196 | 30 (20.7%) | 6.2 | 4.8 (3.4–6.9) | 1.0 (ref) | 5.4 (3.5–8.5) |
| 4–7 | 14,846 (21.4%) | 278,311 | 29 (20.0%) | 4.9 | 5.9 (4.1–8.5) | 1.2 (0.7–2.1) | 8.7 (5.6–13.4) | |
| 8–11 | 11,199 (16.1%) | 209,284 | 39 (26.9%) | 6.0 | 6.5 (4.8–8.9) | 1.7 (0.9–3.1) | 15.8 (10.9–22.9) | |
| 12–20 | 21,402 (30.8%) | 338,843 | 47 (32.4%) | 12.1 | 3.9 (2.9–5.2) | 1.2 (0.6–2.5) | 10.3 (7.0–15.1) | |
| ptrend | 0.27 | 0.28 | 0.008 | |||||
| Attained age (years) (Relates to age at study exit)a | <20 | 15,405 (22.2%) | 410,373 | 18 (12.4%) | 1.1 | 16.1 (10.1–25.5) | 1.0 (ref) | 4.1 (2.5–6.7) |
| 20–29 | 18,877 (27.2%) | 419,216 | 47 (32.4%) | 2.6 | 18.0 (13.5–24.0) | 1.1 (0.5–2.1) | 10.6 (7.8–14.3) | |
| 30–39 | 17,144 (24.7%) | 262,126 | 28 (19.3%) | 4.7 | 6.0 (4.1–8.7) | 0.4 (0.1–1.0) | 8.9 (5.7–13.9) | |
| 40–49 | 10,969 (15.8%) | 120,676 | 36 (24.8%) | 9.3 | 3.9 (2.8–5.3) | 0.3 (0.1–1.2) | 22.1 (14.2–34.3) | |
| 50+ | 7065 (10.2%) | 52,243 | 16 (11.0%) | 11.5 | 1.4 (0.9–2.3) | 0.2 (0.0–0.9) | 8.6 (1.5–49.2) | |
| ptrend | <0.001 | <0.001 | <0.001 | |||||
| Time since 5-year survival (years)b | 0–9 | 23,923 (34.4%) | 565,883 | 36 (24.8%) | 2.2 | 16.0 (11.5–22.2) | 1.0 (ref) | 6.0 (4.2–8.5) |
| 10–19 | 15,801 (22.7%) | 370,881 | 39 (26.9%) | 3.7 | 10.7 (7.8–14.6) | 0.7 (0.4–1.1) | 9.5 (6.7–13.5) | |
| 20–29 | 16,102 (23.2%) | 212,291 | 39 (26.9%) | 7.2 | 5.4 (3.9–7.4) | 0.4 (0.2–0.7) | 15.0 (10.2–22.0) | |
| 30+ | 13,634 (19.6%) | 115,578 | 31 (21.4%) | 16.1 | 1.9 (1.4–2.7) | 0.2 (0.1–0.4) | 12.9 (6.2–26.8) | |
| ptrend | <0.001 | <0.001 | 0.002 | |||||
| Radiotherapy for childhood cancerc | Yes | 20,036 (51.2%) | 471,519 | 95 (79.2%) | 13.1 | 7.2 (5.9–8.9) | 2.6 (1.5–4.5) | 17.4 (13.8–21.9) |
| No | 14,357 (36.7%) | 263,552 | 18 (15.0%) | 6.3 | 2.9 (1.8–4.5) | 1.0 (ref) | 4.4 (2.2–9.0) | |
| Unknown | 4755 (12.1%) | – | 7 (5.8%) | – | – | – | – | |
| Excludedd | 30,312 | 25 | ||||||
| pheterogeneity | <0.001 | <0.001 | <0.001 | |||||
| Chemotherapy for childhood cancerc | Yes | 23,972 (61.2%) | 448,030 | 87 (72.5%) | 6.9 | 12.6 (10.2–15.6) | 2.4 (1.3–4.3) | 17.9 (14.2–22.5) |
| No | 10,335 (26.4%) | 275,190 | 27 (22.5%) | 11.8 | 2.3 (1.6–3.3) | 1.0 (ref) | 5.5 (2.8–10.8) | |
| Unknown | 4841 (12.4%) | – | 6 (5.0%) | – | – | – | – | |
| Excludedd | 30,312 | 25 | ||||||
| pheterogeneity | <0.001 | 0.004 | <0.001 |
Pyrs person-years, Obs observed, Exp expected, SIR standardised incidence ratio, RR relative risk, AER absolute excess risks, HL Hodgkin lymphoma.
aRRs were derived from a model including sex, childhood cancer diagnosis, country, decade of childhood diagnosis, age at childhood diagnosis, and attained age.
bRRs were derived from a model including sex, childhood cancer diagnosis, country, decade of childhood diagnosis, age at childhood diagnosis, and follow-up time.
cRRs were derived from a model including sex, country, age at childhood diagnosis, attained age, and treatment.
dExcluded Nordic countries (Denmark, Sweden, Norway, Finland, Iceland) and Italy population-based data because of lack of treatment data.